RxDoctor Payments Data

William Burke

Geriatric Psychiatry · Omaha, NENPI 1487691663

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $19,725 of the $21,401 with a category attached, or 92.2%. 3 manufacturers reported payments, led by Otsuka Pharmaceutical Development & Commercialization, Inc. at 52.3% of the total. Reporting peaked in 2019 at $13,201 and has fallen 64.4% since, to $4,700 in 2021.

$21,401in general payments, 2019–2025

Across 22 payments — averaging $972.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$11K
  • Biogen$5K
  • Eisai Inc.$5K
$1,852,628in research payments, 2019–2025

Across 26 payments — averaging $71,255 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$693K
  • Eli Lilly$492K
  • Biogen$375K
  • AbbVie$270K
  • Janssen Research & Development, LLC$22K

What the payments were for

  • Consulting fees$19,72592%
  • Travel & lodging$1,3246%
  • Food & beverage$3522%

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few geriatric psychiatry providers in Nebraskato place this figure against a meaningful peer group, so we don't.

Other geriatric psychiatry in Omaha

Where these figures come from

Is this you, or does something look wrong? →